INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$121.17
−0.89%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+42.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jun 4, 2026 | MANHARD KIMBERLY · director | A-Award | 15,000 | $95 |
| Jun 4, 2026 | Vuori Kristiina MD · director | A-Award | 15,000 | $95 |
| Jun 4, 2026 | Kayyem Jon Faiz · director | A-Award | 15,000 | $95 |
| Jun 4, 2026 | FORSYTH DOUGLAS · director | A-Award | 15,000 | $95 |
| Apr 27, 2026 | Matly David · officer: President | A-Award | 50,000 | $129 |
| Oct 9, 2025 | VIKING GLOBAL INVESTORS LP · 10 percent owner | Sale | 308,643 | $32 |
| Oct 9, 2025 | VIKING GLOBAL INVESTORS LP · 10 percent owner | Sale | 25,042 | $32 |
| Oct 9, 2025 | VIKING GLOBAL INVESTORS LP · 10 percent owner | Sale | 16,315 | $32 |
| May 29, 2025 | MANHARD KIMBERLY · director | A-Award | 15,000 | $13 |
| May 29, 2025 | Vuori Kristiina MD · director | A-Award | 15,000 | $13 |
| May 29, 2025 | Kayyem Jon Faiz · director | A-Award | 15,000 | $13 |
| May 29, 2025 | FORSYTH DOUGLAS · director | A-Award | 15,000 | $13 |
| Apr 2, 2025 | Matly David · officer: President | A-Award | 50,000 | $14 |
| Apr 2, 2025 | Deck Kelly · officer: Chief Financial Officer | A-Award | 15,000 | $14 |
| Nov 22, 2024 | Kayyem Jon Faiz · director | Purchase | 18,750 | $14 |
| Nov 22, 2024 | Kayyem Jon Faiz · director | Purchase | 34,843 | $14 |
| Oct 7, 2024 | Vuori Kristiina MD · director | Purchase | 6,667 | $15 |
| Sep 16, 2024 | Lappe Mark · director, officer: Chief Executive Officer | Purchase | 13,037 | $17 |
| Sep 16, 2024 | Lappe Mark · director, officer: Chief Executive Officer | Purchase | 26,963 | $15 |
| Sep 12, 2024 | Vuori Kristiina MD · director | Purchase | 6,457 | $15 |
| Sep 12, 2024 | Vuori Kristiina MD · director | Purchase | 179 | $15 |
| Sep 10, 2024 | Lappe Mark · director, officer: Chief Executive Officer | Purchase | 26,000 | $15 |
| Sep 10, 2024 | Lappe Mark · director, officer: Chief Executive Officer | Purchase | 8,500 | $15 |
| Sep 10, 2024 | Lappe Mark · director, officer: Chief Executive Officer | Purchase | 9,500 | $15 |
| May 30, 2024 | Eckelman Brendan P. · officer: Chief Scientific Officer | Sale | 300,000 | $34 |
| May 24, 2024 | Eckelman Brendan P. · officer: Chief Scientific Officer | M-Exempt | 2,510 | $34 |
| May 24, 2024 | Eckelman Brendan P. · officer: Chief Scientific Officer | M-Exempt | 2,500 | $23 |
| May 8, 2024 | Deck Kelly · officer: Chief Financial Officer | M-Exempt | 17,624 | $11 |
| May 8, 2024 | Deck Kelly · officer: Chief Financial Officer | M-Exempt | 2,087 | $11 |
| Mar 28, 2024 | Deck Kelly · officer: Chief Financial Officer | M-Exempt | 396 | $11 |
Institutional positioning
13F filings over the trailing two quarters
New 76Increased 111Reduced 81Sold out 20
| Filer | Action | Shares | Filed |
|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Reduced | 1,442,707 | May 29, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 1,437,705 | May 15, 2026 |
| MORGAN STANLEY | Increased | 1,308,051 | Aug 13, 2026 |
| PERCEPTIVE ADVISORS LLC | Reduced | 1,297,763 | Aug 14, 2026 |
| MORGAN STANLEY | Reduced | 1,263,078 | May 15, 2026 |
| SANOFI | Unchanged | 1,157,926 | May 7, 2026 |
| Sanofi | Unchanged | 1,157,926 | Jul 28, 2026 |
| VIKING GLOBAL INVESTORS LP | Reduced | 1,123,929 | Aug 14, 2026 |
| HighTower Advisors, LLC | Increased | 870,551 | Aug 5, 2026 |
| HIGHTOWER ADVISORS, LLC | Reduced | 870,200 | May 5, 2026 |
| BANK OF AMERICA CORP /DE/ | Increased | 841,141 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 825,972 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 798,898 | May 13, 2026 |
| Schonfeld Strategic Advisors LLC | Increased | 697,586 | Aug 14, 2026 |
| STATE STREET CORP | Increased | 640,458 | Aug 7, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 4, 2026